In Vivo Toxicology Market Analysis
According to a comprehensive analysis by SNS Insider, the in vivo toxicology market size was valued at USD 7.76 billion in 2024 and is projected to reach USD 18.62 billion by 2032, growing at a robust CAGR of 11.58% during the forecast period of 2025–2032. The market’s growth is attributed to the rising demand for drug safety testing, increased regulatory compliance for preclinical studies, and the expanding outsourcing of toxicity assessments by pharmaceutical and biotech firms.
The need for accurate, reproducible, and reliable toxicological data in drug development and chemical testing has made in vivo testing indispensable, particularly in determining systemic, developmental, and reproductive toxicity endpoints. As regulatory authorities such as the FDA and EMA mandate rigorous toxicity data for investigational new drugs and chemical agents, this has significantly boosted market adoption across sectors.
Get a Free Sample Report of In Vivo Toxicology Market @ https://www.snsinsider.com/sample-request/7528
Growth Drivers:
The surge in preclinical R&D spending by pharmaceutical and biotechnology companies is a primary growth accelerator for the in vivo toxicology market. The market has also witnessed an increased shift toward outsourced testing facilities, particularly among small- and mid-sized drug developers. Outsourcing offers multiple advantages such as cost-effectiveness, access to advanced platforms, and reduced infrastructure burden. While outsourcing holds the majority share, large pharmaceutical companies are increasingly building in-house preclinical testing units to maintain control over study design, ensure data integrity, and achieve regulatory compliance.
Furthermore, the expansion of developmental and reproductive toxicity (DART) testing is another critical growth catalyst. As global awareness around maternal health and reproductive safety rises, regulatory agencies are demanding comprehensive evaluations of fertility, embryo-fetal development, and postnatal outcomes. This demand is particularly relevant amid the rise in fertility-enhancing drugs and prenatal therapeutics.
Technological advancements in toxicological instrumentation, AI-based data interpretation tools, and automated animal handling systems have also played a role in enhancing the accuracy and scalability of in vivo models. These innovations support efficient toxicity assessments and minimize errors, further boosting market demand.
Segmental Insights:
By Product: Instruments accounted for over 58% of the global in vivo toxicology market in 2024. This dominance is credited to the continual technological advancements in imaging, telemetry, and analytical tools essential for animal-based toxicology studies.
By Test Type: Acute toxicity testing emerged as the leading segment, with nearly 34% market share in 2024. These tests are crucial for evaluating immediate adverse effects of substances, particularly during regulatory filings for new chemical entities and therapeutic candidates.
By Testing Facility: Outsourced testing dominated the testing facility segment in 2024 due to its scalability, cost-effectiveness, and access to expert services. However, in-house testing is witnessing rising demand among large pharmaceutical companies striving for direct control and data security.
By Toxicity Endpoint: Systemic toxicity testing accounted for more than 29% of the market share in 2024, due to its mandatory role in assessing multi-organ effects. Meanwhile, the DART segment is rapidly growing, driven by increasing research in reproductive health and fetal development drug safety.
By End User: Pharmaceutical and biotechnology companies led the market with a 45% share in 2024, supported by intensive preclinical research activities and the pressure to accelerate time-to-market for new therapies.
Regional Insights:
North America held a commanding 51.3% share of the global in vivo toxicology market in 2024, with the U.S. alone accounting for USD 3.01 billion. The region’s leadership is reinforced by the presence of major pharmaceutical companies, strong R&D investments, favorable regulatory frameworks, and advanced toxicological infrastructure. The U.S. market is expected to reach USD 6.63 billion by 2032, growing at a CAGR of 10.43%.
Asia Pacific is expected to witness the fastest growth during the forecast period, owing to an expanding biopharmaceutical industry, government initiatives supporting clinical research infrastructure, and growing demand for regulatory toxicology testing services.
Need Any Customization Research on In Vivo Toxicology Market, Enquire Now @ https://www.snsinsider.com/enquiry/7528
Key Companies:
The global in vivo toxicology market is highly competitive with key players focusing on innovation, strategic partnerships, and global expansion. Prominent market participants include:
Charles River Laboratories
Envigo
The Jackson Laboratory
Taconic Biosciences
JANVIER LABS
Thermo Fisher Scientific
Danaher Corporation
Waters Corporation
Agilent Technologies
Shimadzu Corporation
These companies are leveraging technological innovation and global networks to deliver regulatory-compliant and scalable toxicological testing solutions.
Recent Developments:
In March 2024, Charles River Laboratories expanded its safety assessment facilities in North America to meet growing demand for GLP-compliant toxicology testing.
In December 2023, Thermo Fisher Scientific launched an AI-powered toxicity prediction tool integrated with its animal testing platforms to optimize preclinical study outcomes.
In June 2023, Taconic Biosciences entered a strategic alliance with a leading CRO to accelerate IND-enabling toxicity testing for rare disease drug candidates.
Read Our Other Report
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
